TES Pharma announces the publication of a Nature paper “De novo NAD+ synthesis enhances mitochondrial function and improves health” (DOI: 10.1038/s41586-018-0645-6) reporting the in-vivo efficacy of our inhibitors of ACMSD in mouse models of non-alcoholic fatty liver disease (NAFLD) and acute kidney injury (AKI).

The work was performed by scientists lead by Johan Auwerx at EPFL’s Interfaculty Institute of Bioengineering, in collaboration with TES Pharma, the Polytechnic University of Marche and other partners.